Cell Source, Inc. CLCS
Pharmaceutical Preparations · CIK 0001569340 · Fiscal year ends 1231
Revenue
—Unavailable
Fiscal year ended 2024-12-31Operating income
-$3.84M
Fiscal year ended 2024-12-31Free cash flow
—Unavailable
Fiscal year ended 2024-12-31Valuation, from the filing
| Public float | $25.62K | Market value of stock held by non-affiliates, as stated on the cover page for 2024-06-30 |
|---|
| Float per share | $0.00 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
|---|
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2024-12-31 — the year that filing covered.
Cell Source, Inc. (CLCS) reported net income of -$4.51M for the fiscal year ended 2024-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Cell Source, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
Cell Source, Inc. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|
| Revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$3.84M | -$4.33M | -$4.18M | -$4.02M | -$3.64M | -$3.81M | -$2.01M | -$2.29M | —Unavailable | —Unavailable |
|---|
| Net income | -$4.51M | -$5.32M | -$5.17M | -$5.47M | -$4.56M | -$4.48M | -$2.12M | -$3.08M | -$967.78K | -$2.50M |
|---|
| Research & development | —Unavailable | —Unavailable | $1.94M | $1.27M | $834.94K | $2.46M | $274.94K | $637.32K | $554.18K | $392.92K |
|---|
| Weighted-average diluted shares | shares 41.87M | shares 37.79M | shares 34.84M | shares 33.12M | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Pretax income | -$4.51M | -$5.32M | -$5.17M | -$5.47M | -$4.56M | -$4.48M | -$2.12M | -$3.32M | -$967.78K | -$3.08M |
|---|
| Income tax expense | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $0 | $0 | —Unavailable | $0 | $0 | $0 |
|---|
| Diluted EPS | $-0.14 | $-0.17 | $-0.18 | $-0.19 | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $1.28M | $815.95K | $951.78K | $1.10M |
|---|
| General & administrative | $1.94M | $2.60M | $2.18M | $2.70M | $2.64M | $1.17M | $1.28M | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
Cell Source, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|
| Cash & equivalents | —Unavailable | —Unavailable | $222.66K | $93.10K | $241.62K | $27.91K | $18.93K | $371.05K | $3.74K | $6.94K |
|---|
| Total assets | $286.50K | $195.17K | $409.84K | $313.77K | $452.34K | $114.78K | $65.79K | $531.68K | $211.10K | $214.83K |
|---|
| Current assets | —Unavailable | —Unavailable | —Unavailable | $313.77K | $448.84K | —Unavailable | —Unavailable | $531.68K | $210.70K | $213.56K |
|---|
| Total liabilities | $18.82M | $15.81M | $13.04M | $10.14M | $8.40M | $5.86M | $4.99M | $5.09M | $6.45M | $5.97M |
|---|
| Current liabilities | —Unavailable | —Unavailable | —Unavailable | $10.14M | $8.40M | $5.71M | $4.99M | $5.09M | $6.45M | $5.92M |
|---|
| Total equity incl. NCI | -$18.54M | -$15.61M | -$12.63M | -$9.83M | -$7.95M | -$5.74M | -$4.92M | -$4.56M | -$6.24M | -$5.76M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $50.00K | —Unavailable | —Unavailable |
|---|
| Accounts payable | $1.89M | $1.47M | $680.32K | $223.04K | $193.10K | $135.42K | $277.79K | $201.82K | $219.09K | —Unavailable |
|---|
Cash flow
Cell Source, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|
| Operating cash flow | -$2.68M | -$2.35M | -$3.14M | -$3.38M | -$2.77M | -$2.59M | -$2.00M | -$2.29M | -$1.49M | -$2.00M |
|---|
| Capital expenditures | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Investing cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Financing cash flow | $2.74M | $2.15M | $3.27M | $3.23M | $2.99M | $2.60M | $1.65M | $2.66M | $1.49M | $1.99M |
|---|
| Net change in cash | $52.43K | -$200.46K | $129.57K | -$152.02K | $217.21K | $8.97K | -$352.11K | $367.31K | -$3.21K | -$12.54K |
|---|
| Stock-based compensation | —Unavailable | —Unavailable | $77.89K | $419.40K | $791.67K | $844.13K | -$22.50K | $44.72K | $114.76K | $135.88K |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Derived
Cell Source, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 |
|---|
| Free cash flow | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | —Unavailable | —Unavailable | —Unavailable | 0.03x | 0.05x | —Unavailable | —Unavailable | —Unavailable | 0.03x | 0.04x |
|---|
| Revenue YoY growth | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Net margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| R&D / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CLCS in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.